China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026)
China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -5.85% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 44.93% |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 58.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.11% |
| Dec 31, 2025 | -45.73% |
| Sep 30, 2025 | -529.70% |
| Jun 30, 2025 | 522.13% |
| Mar 31, 2025 | 77.44% |
| Dec 31, 2024 | 1,139.96% |
| Sep 30, 2024 | -104.01% |
| Jun 30, 2024 | 65.68% |
| Mar 31, 2024 | 58.57% |
| Dec 31, 2023 | -104.39% |
| Sep 30, 2023 | 2,911.59% |
| Jun 30, 2023 | 58.37% |
| Mar 31, 2023 | -60.33% |
| Dec 31, 2022 | 398.22% |
| Sep 30, 2022 | 96.14% |
| Jun 30, 2022 | -175.31% |
| Mar 31, 2022 | -218.09% |
| Dec 31, 2021 | -136.16% |
| Sep 30, 2021 | -79.16% |
| Jun 30, 2021 | 268.49% |